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Abstract
Objectives To demonstrate the feasibility of MRI-based as-
sessment of the intrahepatic Ho-PLLA-MS biodistribution
after radioembolisation in order to estimate the absorbed
radiation dose.
Methods Fifteen patients were treated with holmium-166
(166Ho) poly(L-lactic acid)-loaded microspheres (Ho-PLLA-
MS, mean 484 mg; range 408–593 mg) in a phase I study.
Multi-echo gradient-echo MR images were acquired from
which R2
* maps were constructed. The amount of Ho-
PLLA-MS in the liver was determined by using the relaxivity
r2
* of the Ho-PLLA-MS and compared with the administered
amount. Quantitative single photon emission computed
tomography (SPECT) was used for comparison with MRI
regarding the whole liver absorbed radiation dose.
Results R2
* maps visualised the deposition of Ho-PLLA-
MS with great detail. The mean total amount of Ho-PLLA-
MS detected in the liver based on MRI was 431 mg (range
236–666 mg) or 89±19 % of the delivered amount (corre-
lation coefficient r00.7; P<0.01). A good correlation was
found between the whole liver mean absorbed radiation dose
as assessed by MRI and SPECT (correlation coefficient
r00.927; P<0.001).
Conclusion MRI-based dosimetry for holmium-166 radio-
embolisation is feasible. Biodistribution is visualised with
great detail and quantitative measurements are possible.
Key Points
• Radioembolisation is increasingly used for treating unre-
sectable primary or metastatic liver tumours.
• MRI-based intrahepatic microsphere biodistribution as-
sessment is feasible after holmium-166 radioembolisation.
• MRI enables quantification of holmium-166 microspheres
in liver in a short imaging time.
• MRI can estimate the whole liver absorbed radiation dose
following holmium-166 radioembolisation.
Keywords Radioembolisation . Holmium .MRI .
Dosimetry . Biodistribution
Introduction
Yttrium-90 (90Y) radioembolisation (RE) is increasingly
used for the treatment of patients with unresectable primary
or metastatic liver tumours [1–6]. The two commercially
available products, SIR-Spheres® (Sirtex Medical Limited,
North Sydney, NSW, Australia) and TheraSphere® (Nordion,
Ottawa, Canada), use empirical methods for dose calculation,
based on body surface area and total liver weight respectively.
However, apart from the total dose delivered to the liver, the
efficacy of RE will largely depend on the intrahepatic dose
distribution or, more specifically, on the ratio between the
tumour absorbed dose and healthy tissue absorbed dose.
G. H. van de Maat (*) : P. R. Seevinck :H. de Leeuw :
M. A. Viergever
Image Sciences Institute, University Medical Center Utrecht,
Q S.459, PO Box 85500, 3508 GA Utrecht, The Netherlands
e-mail: g.h.vandemaat@umcutrecht.nl
M. Elschot :M. L. J. Smits :A. D. van het Schip :
M. A. D. Vente : B. A. Zonnenberg :H. W. A. M. de Jong :
M. G. E. H. Lam :M. A. A. J. van den Bosch : J. F. W. Nijsen :
C. J. G. Bakker
Department of Radiology and Nuclear Medicine,
University Medical Center Utrecht,
Utrecht, The Netherlands
Eur Radiol (2013) 23:827–835
DOI 10.1007/s00330-012-2648-2
Quantitative assessment of the post-administration intrahe-
patic microsphere distribution is therefore indispensable for
evaluation of RE toxicity and efficacy and can potentially be
used for the prediction of patient response and patient-specific
therapeutic dose optimisation. Image-based approaches to as-
sess microsphere distribution after RE have gained interest but
are mostly hampered by the limited imaging possibilities of the
isotope 90Y. Quantitative 90Y-SPECT imaging has limited spa-
tial resolution because it is based on 90Y Bremsstrahlung
[7–10], whereas 90Y-PET has better spatial resolution but low
sensitivity [11, 12]. As a consequence, alternative methods of
visualising the microspheres have been investigated, such as
MR imaging of iron-labelled microspheres [13].
In the past decade, holmium-166 (166Ho) poly(L-lactic
acid)-loaded microspheres (Ho-PLLA-MS) have been de-
veloped as a potential radioembolisation particle [14, 15].
Neutron activated holmium-166 is a β-emitting (Emax01.77
and 1.854 MeV; Iβ048.7 % and 50 %, respectively; T1/20
26.83 h) and γ-emitting (Eγ080.6 keV) lanthanide that, em-
bedded inmicrospheres of poly(L-lactic acid), yields a particle
suitable for internal radiation therapy that can be visualised
with a range of clinical imaging techniques, including SPECT
and MRI. This multimodal imaging has previously been dem-
onstrated in preclinical animal studies [16–18]. It was also
shown that MRI combines high sensitivity with high spatial-
temporal resolution and with superior soft tissue contrast [19]
and thus can be used to cover a broad range of clinically
interesting imaging parameters. More recently, it was shown
for an ex vivo situation that MRI is able to provide a good
measurement of the Ho-PLLA-MS radiation-absorbed dose by
convolution of quantitative MRI data with a 166Ho dose point
kernel [20].
The feasibility of image-guided RE using Ho-PLLA-MS
was tested in a first-time-in-man clinical phase I study. The
aim of the work described in this article was to investigate the
capability of MRI to measure the intrahepatic microsphere
distribution in order to quantify the absorbed radiation dose
in patients treated with Ho-PLLA-MS radioembolisation.
Materials and methods
Patients
To be eligible to enter the phase I study each patient needed
to comply with the following inclusion criteria: written
informed consent; age 18 years or older; presence of liver-
dominant, unresectable, chemorefractory liver metastases of
any primary tumour with at least one measurable lesion of
≥10 mm in the longest diameter on CT; an estimated life
expectancy >3 months; World Health Organisation (WHO)
performance status 0–2; and a negative pregnancy test for
women. Furthermore, patients with contraindications for
MRI were excluded from treatment. Ethics approval for this
study was obtained from the institutional review board; the
study was performed in accordance with the Declaration of
Helsinki and was registered with Clinicaltrials.gov, no.
NCT01031784.
Treatment
Holmium-165 poly(L-lactic acid) microspheres with a mean
diameter of 30 μm (range 20–50 μm) and a holmium
content of 18.7 % (weight/weight) were prepared under
Good Laboratory Practice (GLP) guidelines as previously
described [14]. The amount of microspheres (600 mg) was
weighed, packed in high-density polyethylene vials (Post-
humus Plastics, Beverwijk, The Netherlands) and sent to the
nuclear reactor (Delft University of Technology, Delft, The
Netherlands) for neutron activation [21]. The calculation of
the amount of radioactivity was based on liver weight,
conforming to the clinically used approach for Thera-
Sphere®. The amount of administered 166Ho-radioactivity
was calculated using the target liver absorbed dose in a
dose-escalation fashion (20, 40, 60, or 80 Gy) as previously
described [22]. All patients received whole liver treatment.
The activity to be administered was calculated assuming
homogeneous distribution of the activity in the liver using
the following formula: AHo166 (MBq)0Liver Dose × 63
(MBq/J) × LW where AHo166 is the administered activity,
LW is the liver weight in kg, and Liver Dose is the intended
liver absorbed radiation dose in Gy. While the radioactivity
was different for each patient, the amount of administered
Ho-PLLA-MS was kept constant at 600 mg. Before admin-
istration, the amount of radioactivity in the vials wasmeasured
using a dose calibrator (VDC-404, Veenstra Instrumenten
B.V., Joure, The Netherlands), and the specific activity of
the Ho-PLLA-MS was determined. After administration, ac-
tivity measurements were performed on the administration
system to determine the amount of microspheres that was
actually delivered to the subjects retrospectively.
Radioembolisation procedures
Radioembolisation was performed according to standard
recommendations [23, 24]. Relevant vessels in particular
branches of the hepatic artery supplying organs other than
the liver, e.g., the gastroduodenal artery (GDA) and right
gastric artery (RGA), were coiled during a pre-treatment an-
giographic procedure to prevent extrahepatic deposition of
activity. A scout dose of 99mTc-MAA (150 MBq, 0.8 mg,
TechneScan LyoMaa®, Mallinckrodt Medical B.V., Petten,
The Netherlands) was injected into the hepatic artery followed
by planar gamma camera imaging and SPECT to check for
inadvertent extrahepatic deposition. The 99mTc-MAA lung
shunt was measured by planar scintigraphic imaging, and
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shunt fractions were determined by region of interest (ROI)
analyses [25]. If the lung shunt fraction of 99mTc-MAA was
<20 % and no other extrahepatic deposition of 99mTc-MAA
was detected, treatment with Ho-PLLA-MS was performed
within 2 weeks.
Data acquisition for dosimetry
For intrahepatic biodistribution assessment of themicrospheres,
abdominal SPECT and MRI were performed.
MRI
Magnetic resonance images were acquired 1–2 weeks be-
fore and 1 week after administration of the therapeutic dose
of Ho-PLLA-MS. Since MRI utilises the paramagnetic na-
ture of the microspheres rather than the radioactivity, the
post-therapy imaging time point was of minor relevance,
and post-therapy images were acquired during the patients’
first weekly visit at the outpatient clinic after treatment.
Imaging was performed using a 1.5-T whole body system
(Achieva, Philips Healthcare, Best, The Netherlands)
equipped with a 16-element torso coil. For detection and
quantification of Ho-PLLA-MS, a multi-slice multi-gradient
echo (MGE) sequence was used, acquiring 16 echoes during
breath hold with an in-plane resolution of 2×2 mm2 and a
slice thickness of 6 mm. Imaging parameters included: FOV:
288×384 mm2, number of slices: 45, TR/TE1/ΔTE: 440 ms/
1.33 ms/1.15 ms, flip angle: 50°. Sensitivity encoding
(SENSE) with a factor of 2.5 was used for acceleration result-
ing in an imaging time of 3×19 s during breath hold. For
anatomical information and segmentation purposes, T2-
weighted turbo spin echo (TSE) images were acquired with
identical FOV and voxel size. Imaging parameters included:
TR/TE: 830 ms/80 ms; SENSE factor: 2; imaging time: 2×
19 s during breath hold. In addition, T1-weighted turbo field
echo (TFE) images were acquired using an in-plane resolution
of 1.8×3.6 mm2; slice thickness: 10 mm; TR/TE: 8.5 ms/
4.18 ms; total imaging time: 2×14 s during breath hold.
To determine the sensitivity of MRI for Ho-PLLA-MS, as
expressed by the r2
* relaxivity (relaxation rate per mg/ml
Ho-PLLA-MS), a calibration phantom setup containing
known microsphere concentrations (0, 2.1, 4.1, 6.1 and
8 mg/ml Ho-PLLA-MS in agarose gel) was imaged using
the MGE sequence described above.
SPECT
Single photon emission computed tomography images were
acquired 3–6 days after administration of Ho-PLLA-MS.
The imaging time point did depend on the total activity that
was administered to the patient and was based on the max-
imum tolerated count rate of the SPECT system to acquire
images without dead-time effects. The first nine patients
underwent imaging using a FORTETM dual-headed gamma
camera (FORTETM, Philips Medical Systems, Milpitas, CA,
USA) equipped with gadolinium-153 scanning line sources
for transmission CT. The last six patients underwent imag-
ing using a Siemens Symbia T16 SPECT/CT system (Sie-
mens, Erlangen, Germany), which combines a dual-headed
gamma camera with a 16-slice CT system. Medium energy
collimators were used on both systems. Energy windows
were set at 80.6 keV (15 % window width) for the holmium-
166 photo peak and at 118 keV (12 % window width)
for the correction of downscatter. One hundred twenty
projections of 30 s were acquired in a 180° (FORTE) or
360° (Symbia T16) orbit around the liver. Quantitative
image data were reconstructed to a 1283 matrix size with
an isotropic voxel size of 4.7 mm3 (FORTE) or 4.8 mm3
(Symbia T16), using an ordered subsets expectation max-
imisation algorithm including a hybrid scatter correction
method [26], resulting in an absolute quantitative 3D
activity distribution in MBq/voxel.
Data analyses
Magnetic resonance images were processed using software
code written in MATLAB (MathWorks, Natick, MA, USA).
From the MGE MRI patient data, R2
* values were estimated
voxelwise using a mono-exponential fitting algorithm
weighting all signal amplitudes equally. To minimise the
influence of noise, signal intensities lower than 3σ were
excluded from the fitting procedure, with σ the standard
deviation (SD) of the signal determined in a region with
homogeneous signal intensity and free from Ho-PLLA-MS.
R2
* values were determined for data obtained both before
and after RE. For further analysis, the liver was manually
segmented based on the tissue contrast of the corresponding
T2-weighted TSE images. The distribution of estimated liver
R2
* values was measured, and the mean R2
* value together
with the SD was calculated.
To determine the change in R2
* (ΔR2
*) after therapy, a
baseline R2
* value determined by the mean R2
* of the
liver before Ho-PLLA-MS administration was subtracted
from the post-therapy R2
* maps. Voxelwise concentrations
of Ho-PLLA-MS were determined from the ΔR2
* maps




measured from the calibration phantom setup. Using the
voxel volume and the total volume included in the seg-
mentation, the total amount of Ho-PLLA-MS in the liver
was determined.
For all patients, the MRI-based amount was compared
with the total amount that was assumed to be delivered to
the liver. This amount was determined by correcting the
delivered amount of Ho-PLLA-MS by the 99mTc-MAA lung
shunt fraction and the amount of Ho-PLLA-MS left in the
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administration system. Data from patients who had surgical
clips implanted (as a consequence of former partial liver
resection) were separated from the patients without clips,
and means were also compared separately for these two
groups. This separation was made because metallic surgical
clips are known to distort gradient echo images [27–29] and
hence were suspected to influence MRI-based quantification.
As a final step, the mean radiation absorbed dose was
calculated on a whole liver level using MRI and SPECT
dose maps that were constructed using the method previ-
ously described for an ex-vivo liver model [20]. In short,
MRI concentration values were converted into MBq/voxel
using the voxel size and the specific activity of the micro-
spheres (MBq/mg) at the moment of injection. The SPECT
reconstructions provided an absolute quantitative activity in
MBq/voxel. Both MRI and SPECT activity maps were
convolved with a 166Ho dose point kernel that was calculat-
ed using the Monte Carlo code MCNPX (vs. 2.5.0; LANL,
Los Alamos, NM, USA) according to the method described
in Medical Internal Radiation Dose (MIRD) Pamphlet 17
[30], assuming a tissue density for liver tissue of 1.06 g/cm3
according to International Commission on Radiation Units
and Measurements (ICRU) Report 44 [31]. The voxel size
of the dose point kernel was equal to the native resolution of
the image technique (2×2×6 mm for MRI, 4.7 mm isotropic
for SPECT). After manual co-registration of SPECT maps
to MRI and segmentation, mean liver absorbed dose values
were calculated for both techniques.
Statistical analysis
Descriptive statistics of means, standard deviations and
ranges were calculated for continuous variables. The
paired Student's t-test was used for comparison of means
(two-tailed 95 % confidence interval). Bivariate Pearson's
correlation (one-tailed 95 % confidence interval) was
used for correlation between Ho-PLLA-MS calculations
based on MRI and the actual amount for the whole liver
and the correlation between MRI and SPECT dosimetry
on a whole liver level. SPSS software (SPSS for Windows,
version 13.0; SPSS Inc., Chicago, IL, USA) was used for
all analyses.
Results
Fifteen patients were included in this phase I dose-escalation
study. Nine men and six women, median age 55 years
(range 38–87 years), were treated with escalating whole
liver doses of 20–80 Gy. The median number of liver
tumours was 5 (range 1–21), with a median fractional liver
involvement of 14 % (range 2–52 %), originating from
an ocular melanoma (7 patients), colorectal carcinoma (5
patients), cholangiocarcinoma (2 patients) or breast carcinoma
(1 patient). Five patients had surgical clips implanted in the
liver as a consequence of former partial liver resection (num-
ber of clips ranging from 1 to >20). MRI data were analysed
for 14 patients. One patient was excluded from MRI analysis
because of incomplete data. The patients received a mean of
523 mg Ho-PLLA-MS (range 438–640 mg). Corrected for
shunting to the lungs (mean 7.4 %; range 3.0–13.0 %), the
mean administered amount of Ho-PLLA-MS to the liver was
484 mg (range 408–593 mg; Table 1).
Ho-PLLA-MS caused enhanced MR signal decay after ad-
ministration, translating into high R2
* values (Fig. 1). Strongly
increased R2
* values were observed locally, corresponding to
tumour lesions with high signal intensity on T2-weighted
images. Histograms of the R2
* values found in the liver showed
an overall shift of R2
* values toward higher values and a
broadening of the R2
* distribution after treatment (Fig. 2).
The mean R2
* values, measured over the entire liver for
all patients before treatment (mean 31.5 s−1; range 27.9–
37.3 s−1), significantly increased after administration of Ho-
PLLA-MS (mean 52.7 s−1; range 41.6–78.2 s-1; P<0.001;
Table 1).
From the phantom setup, an r2
* relaxivity of 103±
4 s−1.mg−1.ml was measured for the used Ho-PLLA-MS at
1.5 T, which is in good agreement with the values in the
literature [19, 20]. This value was subsequently used to
calculate Ho-PLLA-MS concentration maps. The concen-
tration maps were comparable to the R2
* maps with rela-
tively high concentrations found at tumour sites (Fig. 3).
From the concentration maps and the volume of the liver,
the amount of Ho-PLLA-MS was calculated. The mean total
amount of Ho-PLLA-MS that was detected in the liver
based on MRI was 431 mg (range 236–666 mg). For all
patients this was 89±19 % (mean±SD) of the amount de-
livered to the liver (correlation coefficient r00.7; P<0.01).
By excluding the data of the patients with surgical clips
implanted in the liver, the mean MRI-based detected frac-
tion increased to 96±13 % (mean±SD; correlation coeffi-
cient r00.8; P<0.01; Table 1). MRI showed that the
presence of surgical clips in the liver led to undetermined
areas (black spots) surrounded by (virtual) high concentra-
tion values (Fig. 4). This led to a poor correlation between
Ho-PLLA-MS amounts calculated on MRI and the actual
delivered amount of Ho-PLLA-MS (correlation coefficient
r00.3; P00.29).
A good correlation was found between the whole liver
mean absorbed radiation dose as assessed by MRI and
SPECT (correlation coefficient r00.93; P<0.001 includ-
ing all patients, correlation coefficient r00.98; P<0.001
excluding patients with surgical clips, correlation coefficient
r00.81; P00.10 for only patients with clips).
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Fig. 1 R2
* maps and SE images (TR/TE: 830 ms/80 ms, flip angle:
90°) before (a+b) and after (c+d) RE. Variations in R2
* values before
RE (a) correspond to variations on SE images (b). After RE, increased
R2
* values were observed at locations with Ho-PLLA-MS deposition
(c), corresponding to tumour lesions with high intensities on SE images
(arrows) (d)
Table 1 Acquired biodistribution data of all 15 patients included in the
phase I dose-escalation study (20, 40 60 and 80 Gy). One patient was
excluded from MRI analyses because of incomplete data. Data of
patients with surgical clips present in the liver are shaded grey.
Administered amounts (admin Ho-PLLA-MS) were determined based
on activity measurements of the administration system and lung shunt
fraction. R2
*, concentration and absorbed dose values are mean values
over the entire liver
Detection of Ho-PLLA-MS in the whole liver 
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408 28.4 ± 12.4 43.3 ± 21.8 0.14 ± 0.21 467 (115)
3 20 5-10 449 31.1 ± 18.6 42.4 ± 36.2 0.11 ± 0.35 287 (64) 6.6 12.5
465 31.8 ± 16.4 45.4 ± 21.2 0.13 ± 0.21 452 (97) 16.4 14.1
489 37.3 ± 24.1 61.4 ± 39.7 0.23 ± 0.39 415 (85) 13.4 11.0
461 30.6 ± 14.8 59.2 ± 23.6 0.28 ± 0.23 447 (97) 15.9 11.9












- 472 33.9 ± 19.7 52.7 ± 36.2 0.19 ± 0.35 351 (74) 19.4 20.9
9 40 10-15 453 30.9 ± 21.7 50.2 ± 29.8 0.28 ± 0.23 495 (109) 29.5 27.7
10 60 - 501 27.9 ± 15.7 42.2 ± 21.4 0.14 ± 0.21 436 (87) 32.4 36.6
11 60 - 485 31.4 ± 19.6 53.8 ± 32.2 0.23 ± 0.30 457 (94) 41.3 36.9
12 60 >20 478 35.8 ± 34.2 45.3 ± 30.0 0.09 ± 0.29 236 (49) 19.6 37.3
13 80 - 593 29.2 ± 13.8 69.4 ± 56.4 0.39 ± 0.55 597 (101)
14 80 1 522 25.5 ± 21.0 41.6 ± 25.7 0.16 ± 0.25 442 (85) 42.0 41.3
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Magnetic resonance imaging displayed the local micro-
sphere distribution in much more detail because of the rela-
tively high in-plane resolution, for example revealing an
absence of Ho-PLLA-MS in the central part of a furthermore
highly targeted tumour in some cases. This situation was
rather obscured in the corresponding SPECT images owing
to the lower resolution and blurring effects (Fig. 5).
Discussion
In this article we presented the first in vivo quantitative MRI
data of 166Ho-poly(L-lactic acid) microspheres for image-
guided radioembolisation using MRI.
Three-dimensional MRI-based assessment of the intra-
hepatic biodistribution of Ho-PLLA-MS was feasible. Ho-
PLLA-MS concentration maps, which were constructed by
using a time series of T2
*-weighted images, clearly showed
the ability of MRI to visualise the intrahepatic biodistribu-
tion of the microspheres. Furthermore, MRI provided both a
quantitative measure of the Ho-PLLA-MS distribution and
anatomical information, enabling direct localisation of the
microsphere deposition within the tissue. MRI detected
89 % of the actual delivered Ho-PLLA-MS in the whole
liver. The mean whole liver absorbed radiation dose calcu-
lated on MRI correlated very well with the absorbed
radiation dose on SPECT. A more detailed intra-tumour
biodistribution assessment was possible using MRI com-
pared with SPECT because of the better spatial resolu-
tion of MRI. The quantitative nature of MRI-based
biodistribution assessment of Ho-PLLA-MS allows for
personalised dosimetry in vivo and may ultimately lead












Fig. 2 Typical histogram of R2
* values measured in the whole liver of
a patient before (– –) and after (―) adminstration of Ho-PLLA-MS.
After administration the curves shifted toward higher values and a
broader distribution of R2
* values was observed
Fig. 3 MRI-based concentration maps (a) after Ho-PLLA-MS admin-
istration, MRI-based absorbed dose maps (b) together with their
corresponding SPECT images (c) and T1-weighted images (d) (TR/
TE: 8.5 ms/4.18 ms, flip angle: 10°). The concentration maps were
constructed from normalised R2
* maps by using the r2
* relaxivity of
Ho-PLLA-MS. MRI-based dose maps were constructed by applying a
dose point kernel after conversion of concentrations Ho-PLLA-MS to
MBq/voxel. MRI-based concentration and absorbed dose correspond
to the activity distribution on the SPECT images (c) and the tumour
sites on T1-weighted images (d) (arrows)
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Compared with the actual administered amount of Ho-
PLLA-MS in the liver, determined based on the injected
amount and taking into account the 99mTc-MAA-based lung
shunt fraction, the MRI quantification method presented
in this work showed on average an underestimation. As
shown, this was in part due to the presence of surgical clips
(Fig. 4). These clips induced field distortions, resulting in
large MR signal voids surrounded by large R2
* values.
Therefore, locally the amount of Ho-PLLA-MS cannot be
determined resulting in an underestimation of the micro-
sphere amount in the vicinity of the clips. Although the
presence of surgical clips does not necessarily lead to a
contraindication for MRI-based dosimetry, biodistribution
measurements in the vicinity of the clips should be inter-
preted with care. Another source of the discrepancy between
the MRI-based amount and the amount delivered may be the
use of 99mTc MAA as a predictor of the lung shunt fraction.
Although used to correct for extrahepatic deposition in order
to estimate the Ho-PLLA-MS liver amount, it is known that,
because of a number of dissimilarities between 99mTc MAA
and Ho-PLLA-MS such as size, shape and density, 99mTc
MAA is not the optimal microsphere analogy [6]. Incorrect
assessment of the lung shunt fraction may have led to an
erroneous estimation of the amount of Ho-PLLA-MS deliv-
ered in the liver. This explanation is supported by the good
correlation that was found between the MRI-based mean liver
absorbed dose and the absorbed dose based on the more
conventional method of image-based dosimetry, SPECT.
Quantification errors may also arise from the need to
correct for baseline R2
* values in order to determine ΔR2
*.
ΔR2
* values were calculated by subtracting the mean liver
R2
* value before administration from the post-treatment R2
*
maps. Because of the variance of R2
* in the absence of
microspheres as a result of tissue characteristics (Fig. 1),
over- or underestimations will be introduced at the voxel
level. The bias introduced in ΔR2
* will depend on the local
voxel R2
* value with respect to the mean R2
* over the whole
VOI. In addition to these variations over space, changes
may occur in tissue T2 in the time interval between pre-
and post-therapy imaging. Such changes may occur, for
example, because of short-term therapy-induced oedema
[32], which leads to increasing T2 values, and thus decreas-
ing R2 values, owing to the higher water content as is
generally reflected by hyperintense areas on T2-weighted
images [33]. A decrease in tissue R2 may therefore counter-
act the increase in R2
* because of Ho-PLLA-MS leading to
an underestimation of Ho-PLLA-MS concentration.
To minimise these quantification errors, voxel-based sub-
traction of post- and pre-therapy maps seems to be crucial.
Manual or (semi-) automatic registration of these maps may
partly solve the problem, but a more robust solution will be to
integrateMR imaging as part of the RE procedure. Data needed
to construct the concentration maps shown in this work were
acquired within 1 min, and data processing can be performed
within several minutes. Considering this short time scale, it is
feasible to perform personalised MRI-based dosimetry during
the actual RE procedure. This would enable fast verification
and give the opportunity, if necessary, to immediately adjust the
RE procedure. Moreover, MRI would enable monitoring of the
administration of the Ho-PLLA-MS in real time. This has
previously been demonstrated in a pig model [34].
Fig. 4 MRI-based Ho-PLLA-
MS concentration maps before
(a) and after (b) radioembolisa-
tion in a patient with multiple
surgical clips after partial liver
resection. At the location of the
clips (arrows), quantification
failed (black spots), while in the
near vicinity extremely high
concentration values were
found (white rings)
Fig. 5 Ho-PLLA-MS deposition around tumours. MRI-based concen-
tration maps (a) show more detail (higher resolution) about the distri-
bution of the microspheres than the SPECT-based activity maps. The
Ho-PLLA-MS are primarily distributed in the peripheral parts of the
tumour (a). This is less pronounced on the SPECT images (b)
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The first MRI data of patients treated with 166Ho-poly
(L-lactic acid) microspheres show the feasibility of MRI-
based dosimetry for radioembolisation. Intrahepatic micro-
sphere biodistribution can be visualised with great detail,
and a good quantitative measurement of the absorbed
radiation dose can be obtained within several minutes of
the radioembolisation procedure. Biodistribution assess-
ment in the vicinity of surgical clips should be interpreted
with care.
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